Genetic polymorphisms in TCF7L2 affect the therapeutic response to insulin secretagogues (e.g., sulfonylureas) and increase the risk of T2D, with the underlying mechanism of impaired insulinotropic action of incretin hormones [46,47,48,49]. The gene discussed is INS; the disease is type 2 diabetes mellitus.